Almeda-Valdes P, Velasco DVG, Campos OA, et al. The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-size adipocytes. Eur J Endocrinol. 2019;180(2):99-107. doi:10.1530/EJE-18-0677.
Rusu V, Hoch E, Mercader JM, et al. Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms. Cell. 2017;170(1):199-212.e20. doi:10.1016/j.cell.2017.06.011.
Birsoy K, Wang T, Possemato R, et al. MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors. Nat Genet. 2013;45(1):104-8. doi:10.1038/ng.2471.
Consortium SIGMATD 2, Williams AL, Jacobs SBR, et al. Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico. Nature. 2014;506(7486):97-101. doi:10.1038/nature12828.